Ismail Kola - UCB SA Insider

UCBJY -- USA Stock  

USD 46.45  0.002  0.0043%

  EVP
Dr. Ismail Kola was Executive Vice President, New Medicines Head and Chief Scientific Officer and Member of the Executive Committee of UCB S.A. since November 2009. He joined the Company in November 2009. He holds a Doctorate in Philosophy in Medicine from the University of Cape Town, South Africa. He also holds a BS from the University of South Africa UNISA and a Bachelors degree from Rhodes University. He joined the Company from Schering Plough Corporationrationration where he was Senior Vice President, Discovery Research and Early Clinical Research Experimental Medicine, ScheringPlough Research Institute, the pharmaceutical research arm of ScheringPlough Corporationrationration, and Chief Scientific Officer, Schering Plough Corporationrationration. He came to ScheringPlough from Merck, where he was Senior Vice President and Site Head, Basic Research. He also chaired Merck Antibacterial and Antifungal Worldwide Business Strategy Team. Prior to that, he was Vice President, Research, and Global Head, Genomics Science and Biotechnology, with Pharmacia Corporationrationration. Prior to his move to Industry, Ismail was Professor of Human Molecular Genetics, Monash University Medical School and Director of the Research Center for Functional Genomics and Human Disease. He was at Monash for approximately 15 years. He holds Adjunct Professorships of Medicine at Washington University, St Louis, Missouri, United States, and Monash University Medical School, Melbourne, Australia a Foreign Adjunct Professorship at The Karolinska Institute, Stockholm, Sweden and is a William Pitt Fellow at Pembroke College, Cambridge University, United Kingdom. He is Member of the Board of Athersys Inc., Biotie Therapies, and Astex Pharmaceuticals.
Age: 59  EVP Since 2009  Ph.D    
32 2 559 99 99  http://www.ucb.com
Kola holds a Doctorate in Philosophy in Medicine from the University of Cape Town, South Africa. He also holds a BS from the University of South Africa UNISA and a Bachelors degree from Rhodes University. He joined the Company from Schering Plough Corporationrationrationration where he was Senior Vice President, Discovery Research and Early Clinical Research & Experimental Medicine, ScheringPlough Research Institute, the pharmaceutical research arm of ScheringPlough Corporationrationrationration, and Chief Scientific Officer, Schering Plough Corporationrationrationration. He came to ScheringPlough from Merck, where he was Senior Vice President and Site Head, Basic Research. He also chaired Merck Antibacterial and Antifungal Worldwide Business Strategy Team. Prior to that, he was Vice President, Research, and Global Head, Genomics Science and Biotechnology, with Pharmacia Corporationrationrationration

Ismail Kola Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 7.3 % which means that it generated profit of $7.3 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 15.56 % meaning that it generated $15.56 on every $100 dollars invested by stockholders.
The company has accumulated 1.94 B in total debt with debt to equity ratio (D/E) of 28.0 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. UCB SA has Current Ratio of 1.2 suggesting that it may not have the ability to pay its financial obligations in time and when they become due.

Similar Executives

Found 7 records

EVP Since

Suzanne HooperJazz Pharmaceuticals Public Lim
2012
Madhavan BalachandranAmgen
2012
Paula SwainIncyte Corporation
2002
Robert BaffiBioMarin Pharmaceutical
2009
Anthony HooperAmgen
2011
Karen EtchbergerCSL Limited
2013
Reid HuberIncyte Corporation
2014

Entity Summary

UCB SA, a biopharmaceutical company, focuses on the discovery and development of medicines and solutions for people living with severe diseases of the immune system or of the central nervous system. UCB SA was founded in 1928 and is based in Brussels, Belgium. UCB SA operates under Biotechnology classification in USA and traded on OTC Market. It employs 7500 people.UCB SA (UCBJY) is traded on OTC Market in USA. It is located in All?e de la Recherche, 60 and employs 7,500 people.

UCB SA Leadership Team

Pascale Richetta, Executive Vice President Bone Patient Value Unit Head, Member of the Executive Committee
Detlef Thielgen, CFO and Executive VP
Kay Davies, Independent Director
Dirk Teuwen, VP Corporate Societal Responsibility
Anna Richo, Executive VP and General Counsel
Viviane Monges, Independent Non-Executive Director
Gerhard Mayr, Non-Executive Chairman of the Board
Cyril Janssen, Director
Cedric Rijckevorsel, Director
JeanChristophe Tellier, Chairman of the Executive Committee, CEO
Arnoud Calesberg, Non-Executive Director
Mark McDade, COO and Executive VP
Xavier Michel, Vice President and Secretary General
Dhavalkumar Patel, Executive Vice President Chief Scientific Officer, Member of the Executive Committee
Bharat Tewarie, Executive Vice President Chief Marketing Officer
Roch Doliveux, Chairman of the Executive Committee, CEO, Executive Director
Norman Ornstein, Non-Executive Independent Director
Jeff Wren, Executive Vice President Neurology ? Patient Value Unit Head
JeanPierre Kinet, Non-Executive Independent Director
Antje Witte, VP of Investor Relations
Alice Dautry, Independent Director
Harriet Edelman, Non-Executive Independent Director
Ulf Wiinberg, Independent Director
Thomas McKillop, Non-Executive Independent Director
Charl Zyl, Executive Vice President Head of Patient Value Operations, Member of the Executive Committee
France Nivelle, VP Global Communication
Fabrice Enderlin, Executive Vice President - Human Resources & Communication, Member of the Executive Committee
Pierre Gurdjian, Independent Director
Ismail Kola, Chief Scientific Officer, Head of New Medicines Patient Value Unit and Executive VP
Emmanuel Caeymaex, Executive Vice President Immunology - Patient Value Unit Head
Evelyn Bergendal, Non-Executive Vice Chairwoman of the Board
Iris LoewFriedrich, Executive Vice President Chief Medical Officer
CharlesAntoine Janssen, Non-Executive Director
Albrecht Graeve, Non-Executive Independent Director
JeanLuc Fleurial, Executive Vice President Chief Talent Officer, Member of the Executive Committee
Alexander Moscho, Executive Vice President Chief Strategy Officer, Member of the Executive Committee

Stock Performance Indicators

Did you try this?

Run Aroon Oscillator Now

   

Aroon Oscillator

Analyze current equity momentum using Aroon Oscillator and other momentum ratios
All  Next Launch Aroon Oscillator

Also Currentnly Active

Purchased over 400 shares of
few hours ago
Traded for 6.36
Purchased a lot of shares of
few hours ago
Traded for 153.4
Purchased few shares of
few hours ago
Traded for 1161.22
Also please take a look at World Market Map. Please also try Volatility Analysis module to get historical volatility and risk analysis based on latest market data.
Search macroaxis.com